Kitty Yale

2.6k total citations · 3 hit papers
21 papers, 1.9k citations indexed

About

Kitty Yale is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Kitty Yale has authored 21 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 11 papers in Virology and 10 papers in Epidemiology. Recurrent topics in Kitty Yale's work include HIV Research and Treatment (11 papers), HIV/AIDS drug development and treatment (11 papers) and Liver Disease Diagnosis and Treatment (9 papers). Kitty Yale is often cited by papers focused on HIV Research and Treatment (11 papers), HIV/AIDS drug development and treatment (11 papers) and Liver Disease Diagnosis and Treatment (9 papers). Kitty Yale collaborates with scholars based in United States, United Kingdom and France. Kitty Yale's co-authors include Andrew Cheng, Brian P. Kearney, Edwin DeJesus, Lijie Zhong, Peter Ruane, Kirsten White, Javier Szwarcberg, Tim Rolph, Brittany de Temple and Guy Neff and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Kitty Yale

19 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

2021 255 citations Stephen A. Harrison, Peter Ruane et al. Nature Medicine profile →
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

2023 146 citations Stephen A. Harrison, Juan P. Frías et al. The Lancet. Gastroenterology & hepatology profile →
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH

2025 19 citations Mazen Noureddin, Guy Neff et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kitty Yale United States	16	1.2k	837	646	389	328	21	1.9k
Xuelian Wei United States	17	1.6k 1.4×	1.0k 1.2×	254 0.4×	886 2.3×	194 0.6×	33	2.0k
Mark Bloch Australia	17	669 0.6×	391 0.5×	351 0.5×	481 1.2×	175 0.5×	40	1.5k
Sonia Rodríguez‐Nóvoa Spain	26	1.5k 1.3×	745 0.9×	689 1.1×	532 1.4×	140 0.4×	72	2.2k
Christoph Wyen Germany	22	1.0k 0.8×	604 0.7×	293 0.5×	307 0.8×	73 0.2×	70	1.7k
Antonio Chirianni Italy	17	553 0.5×	429 0.5×	292 0.5×	444 1.1×	68 0.2×	70	1.1k
Mustafa A. Noor United States	14	900 0.8×	749 0.9×	208 0.3×	1.1k 2.8×	184 0.6×	20	1.6k
Beverly Alston‐Smith United States	13	421 0.4×	281 0.3×	329 0.5×	610 1.6×	46 0.1×	23	1.0k
Jean-Guy Baril Canada	17	751 0.6×	751 0.9×	245 0.4×	431 1.1×	155 0.5×	51	1.3k
Paola Meraviglia Italy	19	941 0.8×	556 0.7×	368 0.6×	330 0.8×	58 0.2×	61	1.3k
María Saumoy Spain	18	646 0.5×	456 0.5×	206 0.3×	431 1.1×	78 0.2×	61	915

Countries citing papers authored by Kitty Yale

Since Specialization

Citations

This map shows the geographic impact of Kitty Yale's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kitty Yale with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kitty Yale more than expected).

Fields of papers citing papers by Kitty Yale

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kitty Yale. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kitty Yale. The network helps show where Kitty Yale may publish in the future.

Co-authorship network of co-authors of Kitty Yale

This figure shows the co-authorship network connecting the top 25 collaborators of Kitty Yale. A scholar is included among the top collaborators of Kitty Yale based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kitty Yale. Kitty Yale is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Noureddin, Mazen, Juan P. Frías, Guy Neff, et al.. (2025). Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet. 406(10504). 719–730. 5 indexed citations

Noureddin, Mazen, Mary E. Rinella, Naga Chalasani, et al.. (2025). GS-012 Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, doubleblind, placebo-controlled, phase 2b trial (SYMMETRY). Journal of Hepatology. 82. S8–S9.

Lucas, Kathryn Jean, Doreen Chan, Erik J. Tillman, et al.. (2024). 897-P: Insulin-Sensitizing Effects of Efruxifermin Improve Glycemic Control in Patients with MASH and Type 2 Diabetes. Diabetes. 73(Supplement_1). 1 indexed citations

Shumbayawonda, Elizabeth, Anneli Andersson, Kitty Yale, et al.. (2024). Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH. Journal of Hepatology. 82(3). 438–445. 14 indexed citations

Harrison, Stephen A., Juan P. Frías, Kathryn Jean Lucas, et al.. (2024). Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study. Clinical Gastroenterology and Hepatology. 23(1). 103–113. 37 indexed citations

Harrison, Stephen A., Juan P. Frías, Guy Neff, et al.. (2023). Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet. Gastroenterology & hepatology. 8(12). 1080–1093. 146 indexed citations breakdown →

Harrison, Stephen A., Peter Ruane, B. Freilich, et al.. (2022). A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Reports. 5(1). 100563–100563. 72 indexed citations

Tillman, Erik R., Reshma Shringarpure, Guy Neff, et al.. (2022). Efx treatment improved histopathology and non-invasive markers of liver injury and fibrogenesis to a similar extent in NASH patients with high-risk PNPLA3 genotypes, compared to those with lowest genetic risk: a post-hoc analysis of balanced study. Journal of Hepatology. 77. S719–S719.

Harrison, Stephen A., Peter Ruane, B. Freilich, et al.. (2021). Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nature Medicine. 27(7). 1262–1271. 255 indexed citations breakdown →

10.

Ruane, Peter, Edwin DeJesus, Daniel Berger, et al.. (2013). Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(4). 449–455. 247 indexed citations

11.

Mills, Anthony, Calvin Cohen, Edwin DeJesus, et al.. (2013). Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens. HIV Clinical Trials. 14(5). 216–223. 61 indexed citations

12.

Sax, Paul E., Edwin DeJesus, Anthony Mills, et al.. (2012). Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. The Lancet. 379(9835). 2439–2448. 335 indexed citations

13.

DeJesus, Edwin, Jürgen K. Rockstroh, Keith Henry, et al.. (2012). Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. The Lancet. 379(9835). 2429–2438. 256 indexed citations

14.

Cohen, Calvin, Richard Elion, Peter Ruane, et al.. (2011). Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 25(6). F7–F12. 93 indexed citations

15.

Randell, Paul, Akil Jackson, Lijie Zhong, Kitty Yale, & Graeme Moyle. (2010). The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. Antiviral Therapy. 15(2). 227–233. 36 indexed citations

16.

Kearney, Brian P., Kitty Yale, Jaymin Shah, Lijie Zhong, & John F. Flaherty. (2006). Pharmacokinetics and Dosing Recommendations of Tenofovir Disoproxil Fumarate in Hepatic or Renal Impairment. Clinical Pharmacokinetics. 45(11). 1115–1124. 58 indexed citations

17.

Gafni, Rachel I., Rohan Hazra, James C. Reynolds, et al.. (2006). Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy: Impact on Bone Mineral Density in HIV-Infected Children. PEDIATRICS. 118(3). e711–e718. 133 indexed citations

18.

Hazra, Rohan, Rachel I. Gafni, Frank Maldarelli, et al.. (2005). Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy for Pediatric HIV Infection. PEDIATRICS. 116(6). e846–e854. 72 indexed citations

19.

Smith, Patrick F., Brian P. Kearney, Julie Bullock, et al.. (2004). Effect of Tenofovir Disoproxil Fumarate on the Pharmacokinetics and Pharmacodynamics of Total, R‐, and S‐Methadone. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 24(8). 970–977. 16 indexed citations

20.

Hazra, Rohan, Frank M. Balis, Antonella N. Tullio, et al.. (2003). Single-Dose and Steady-State Pharmacokinetics of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Children. Antimicrobial Agents and Chemotherapy. 48(1). 124–129. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact